skip to Main Content
Black and white image of a cancer cell from under a microscope

Immunotherapy for Pancreatic Neuroendocrine Tumors

This trial is active, but no longer recruiting participants. Pancreatic neuroendocrine tumors (P-NETs) make up less than 5 percent of all pancreatic cancers. Unlike pancreatic ductal adenocarcinomas (PDAs), P-NETs originate in the hormone-making islet cells of the pancreas, respond to different treatments, and have an overall survival rate higher than PDAs. In a clinical trial,…

Back To Top